

HORIZON-HLTH-2024-TOOL-05-06-two-stage, RIA



Proposed Approach

What is your understanding of the part of the problem you can solve?

development of nanosystems carrying anticancer drugs from their initial design, preclinical testing of efficacy, pharmacokinetics, and toxicity to the preparation of detailed protocols needed for the first phase of their clinical studies.

What is your understanding of the part of the problem you can solve?

WG1: Manufacturing Nanodrugs

WG2: Physico-Chemical Characterization of Nanodrugs

WG3: Preclinical Studies of Nanodrugs

If you are looking for partners, what type of partners are you looking for?

Academics, SEM with expertise above

Experience

What previous, relevant, work or track record can you bring to the team?

Professor Nguyễn Thị Kim Thanh, FRSC, FInstP, FIMMM FRSB held a prestigious Royal Society University Research Fellowship (2005-2014). Full Professor in Nanomaterials since 2013 at UCL, Vice Dean for Innovation and Enterprise at Faculty of Maths and Physical Sciences.

She leads a group conducting cutting edge interdisciplinary and innovative research on the design, and synthesis of magnetic and plasmonic nanomaterials for biomedical applications

Include your ability to attract the 'Big Names' in the sector (e.g. leading academics, major thought leaders) Chair of WG and in MC in 3 COST ACTIONS

Organisational Capabilities

COST ACTION CA17140

Cancer Nanomedicine – from the Bench to the Bedside (Nano2Clinic)

Synthesis and Biofunctionalisation and characterisation of nanomaterials for healthcare

Administrative Information

Partner

Prof NGUYEN TK THANH

ntk.thanh@ucl.ac.uk

<http://www.ntk-thanh.co.uk>

University College London, UK

PIC: **999975620**

&

<https://www.cost.eu/actions/CA17140/>